NYSE:BXLT (BXLT) (BXLT) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free BXLT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$46.02▼$46.0250-Day Range N/A52-Week Range$29.83▼$46.52VolumeN/AAverage Volume12.66 million shsMarket CapitalizationN/AP/E Ratio15.49Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (BXLT) alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About (BXLT) Stock (NYSE:BXLT)Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta's categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… BXLT Stock News HeadlinesApril 5, 2024 | morningstar.comAnyMind Group Inc 5027February 25, 2024 | morningstar.comIDICO Corp JSC Ordinary Shares IDCApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.February 20, 2024 | morningstar.comHana Financial Group Inc 086790September 15, 2023 | thestreet.comBaxter Int'l. (BAX) Stock Price Target Lowered by AnalystsAugust 25, 2023 | thestreet.comAllergan Could Buy These Drug Companies Now That the Pfizer Merger Is ScuttledJuly 25, 2023 | thestreet.com4 Smart Stocks to Add to Your Portfolio in 2016, from Recon’s Kevin KellyMay 31, 2023 | msn.comFed Beige Book: Pace of hiring and pricing is slowingApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.May 31, 2023 | msn.comAdidas' remaining Yeezy sneakers go on saleMarch 29, 2023 | msn.comSuburban businesses accuse convicted credit card fraudster John Hancock of more crimesFebruary 17, 2023 | msn.comChevron to send over 100,000 bpd of Venezuelan oil to U.S. this monthDecember 23, 2022 | msn.comNew Vernon, B.C. supportive housing building set to openDecember 23, 2022 | msn.com1 victim identified in double shooting in College Hill, police sayNovember 16, 2022 | msn.comCrews continue working to restore water service in ZavallaOctober 4, 2022 | msn.comMorgan City man arrested for stealing car, multiple active warrants foundSeptember 8, 2022 | msn.comEvo Morales accuses Bolivian ministers of executing «a black plan» against himAugust 23, 2022 | thestreet.comPayPal Is Cramer and Mohr’s Newest Addition to the AAP PortfolioAugust 12, 2022 | msn.comVideo Explains How the Earth Is Spinning Faster Lately And Viewers Have CommentsMarch 1, 2022 | thestreet.com4 Pharmaceutical Stocks to Buy in Wake of Shire-Baxalta BidSee More Headlines Receive BXLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (BXLT) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/28/2016Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNYSE:BXLT CUSIPN/A CIK1620546 Webwww.baxalta.com Phone+1-224-9402000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio15.49 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report BXLT Stock Analysis - Frequently Asked Questions How were (BXLT)'s earnings last quarter? (BXLT) (NYSE:BXLT) released its earnings results on Thursday, April, 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.01. The biotechnology company had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.47 billion. The business's revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.40 EPS. Is (BXLT) a good dividend stock? (BXLT) (NYSE:BXLT) pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.00%. The dividend payout ratio is 9.43%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for BXLT. What other stocks do shareholders of (BXLT) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (BXLT) investors own include Baxter International (BAX), Hawkins (HWKN), AbbVie (ABBV), Allergan (AGN), Vertex Pharmaceuticals (VRTX), Alibaba Group (BABA), Bank of America (BAC), Edwards Lifesciences (EW), Gilead Sciences (GILD) and Micron Technology (MU). This page (NYSE:BXLT) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHow to camouflage a factory of 53,000 workersStansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (BXLT) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
